Cyclophilin A in Ruptured Intracranial Aneurysm

Abstract

Cyclophilin A (CyPA), an oxidative stress-induced factor, was found to play an important role in the aneurysm formation. Our working hypothesis was that the plasma level of CyPA in ruptured intracranial aneurysm could predict the neurological outcome.From 2011 to 2013, a total of 36 patients with ruptured saccular intracranial aneurysm were recruited in our study. Before coil embolization, we draw blood samples at the orifice of a culprit aneurysm and in the remote peripheral vein for measurements of the CyPA levels. We utilized the modified Rankin scale 30 days after aneurysm rupture as the outcome measure. Generalized linear models were used to estimate the adjusted odds ratios of the poor neurological outcome given the presence of high plasma level of CyPA.The aneurysmal and venous CyPA levels were significantly associated with the initial clinical severity (P = 0.004 and 0.03, respectively) and 30-day outcome (P = 0.01 and 0.02, respectively). The aneurysmal CyPA levels modestly correlated with age and high Fisher grade (ρ = 0.39 and 0.41; P = 0.02 and 0.01, respectively). The aneurysmal CyPA levels strongly correlated with the venous counterpart (ρ = 0.89; P < 0.001). Patients with high levels of aneurysmal CyPA were 15.66 times (95% CI, 1.48–166.24; P = 0.02) more likely to have worse neurological outcome than those with the low levels after adjustment of the age, gender, and the documented confounding factors.High plasma level of CyPA is a significant prognostic biomarker for poor neurological outcome in patients with ruptured intracranial aneurysm.

A Two-Gene-Based Diagnostic Signature for Ruptured Intracranial Aneurysms

“…Quan et al reported that the expression of F2-isoprostanes and F4-neuroprostanes in the plasma of patients with IAs is significantly upregulated compared with healthy subjects, and these may be considered potential biomarkers for IA development (26). Kao et al identified that patients with high levels of aneurysmal cyclophilin A (CyPA) in plasma were 15.66 times more likely to have worse neurological outcomes than those with low levels; this may be a significant prognostic biomarker for poor neurological outcome in IA (27). Compared with serum or tissue samples, blood samples are readily available.…”

Cyclophilin A: a novel biomarker for cardiovascular disease in patients with type 2 diabetes

“…It was previously reported that the plasma levels of CyPA are significantly higher in patients with CAD with type 2 DM [13]. Indeed, several studies have demonstrated the role of CyPA as a biomarker of CADs [14][15][16][17][18]. Huang et al [14] reported that the plasma levels of CyPA 1 month after AMI predict the prognosis of the patients.…”

Contribution of blood-brain barrier-related blood-borne factors for Alzheimer’s disease vs. vascular dementia diagnosis: A pilot study

“…CyPA is secreted by activated macrophages, lymphocytes, and platelets and mediates the harmful effects of pericytes on BBB disruption ( Seizer et al, 2010 , 2015 , 2016 ; Pan et al, 2020 ). Previous studies have shown that the plasma CyPA level is a new biomarker for the diagnosis of coronary artery disease (CAD) and renal disease progression and is used as a prognostic factor in patients with ruptured intracranial aneurysms ( Satoh et al, 2013 ; Ramachandran et al, 2014 ; Kao et al, 2015 ; El-Ebidi et al, 2020 ; Rath et al, 2020 ). MMP9 is involved in the increase of BBB permeability during AD, which accelerates its onset ( Barr et al, 2010 ; Shackleton et al, 2019 ).…”